The trajectory of Viagra, originally marketed by copyright, presents a intricate case study for backers considering the pharmaceutical sector. While its initial success and generation of billions in earnings , the patent end has opened the floodgates for generic medications, significantly eroding profit prospects . This shift raises concerns about